Tyson Kim
Amministratore Delegato presso SYNTEKABIO, INC.
Profilo
Tyson Kim currently works at Syntekabio, Inc, as Chief Executive Officer from 2015 and Radexel Co. Ltd., as Chief Executive Officer.
Posizioni attive di Tyson Kim
| Società | Posizione | Inizio |
|---|---|---|
| SYNTEKABIO, INC. | Amministratore Delegato | 01/01/2015 |
Radexel Co. Ltd.
 Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SYNTEKABIO, INC. | Technology Services |
| Aziende private | 1 |
|---|---|
Radexel Co. Ltd.
Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Health Technology |
- Borsa valori
- Insiders
- Tyson Kim
